Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 9 chart positions in 9 markets.
By chart position
- 🇨🇱CL · Medicine#2710K to 30K
- 🇮🇸IS · Medicine#723K to 10K
- 🇦🇷AR · Medicine#763K to 10K
- 🇵🇹PT · Medicine#110500 to 3K
- 🇸🇦SA · Medicine#119500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
9.5K to 34K🎙 ~2x weekly·100 episodes·Last published 1w ago - Monthly Reach
Unique listeners across all episodes (30 days)
19K to 68K🇨🇱44%🇮🇸15%🇦🇷15%+6 more - Active Followers
Loyal subscribers who consistently listen
7.6K to 27K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHost
Recent guests
No guests detected in recent episodes.
Recent episodes
E136: Secukinumab in PMR (REPLENISH)
Jun 15, 2026
13m 39s
E135: IL17 and a GLP1?
Apr 30, 2026
11m 03s
E134: Brepocitinib in Dermatomyositis (VALOR)
Apr 17, 2026
14m 58s
E133: Obinutuzumab for SLE (ALLEGORY)
Mar 19, 2026
15m 21s
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
Mar 5, 2026
13m 54s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/15/26 | E136: Secukinumab in PMR (REPLENISH) | Big trial this week in the NEJM investigating the IL17 inhibitor secukinumab in PMR. Well worth a read, I would bet on FDA approval in the near future. Some interesting tidbits and of course a weird safety thing we now have to grapple with. Be sure to go to boardsbank.com! Free rheumatology board review, >1000 questions! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2602567 | 13m 39s | ||||||
| 4/30/26 | E135: IL17 and a GLP1?✨ | IL17 inhibitorsGLP1 inhibitors+3 | — | ixekizumabtirzepatide+2 | — | IL17GLP1+5 | — | 11m 03s | |
| 4/17/26 | E134: Brepocitinib in Dermatomyositis (VALOR)✨ | dermatomyositisbrepocitinib+3 | — | brepocitinibautoimmunedevreport.substack.com+2 | — | brepocitinibdermatomyositis+3 | — | 14m 58s | |
| 3/19/26 | E133: Obinutuzumab for SLE (ALLEGORY)✨ | rheumatologyclinical trials+3 | — | obinutuzumabNEJM+2 | — | obinutuzumabSLE+3 | — | 15m 21s | |
| 3/5/26 | E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)✨ | osteoporosisromosozumab+4 | — | Romosozumab vs teriparatide for osteoproosishttps://pubmed.ncbi.nlm.nih.gov/28755782/ | — | osteoporosisromosozumab+6 | — | 13m 54s | |
| 1/21/26 | E131: A Sham-Controlled Sham of a Trial: RESET-RA✨ | rheumatoid arthritisvagal nerve stimulation+3 | — | NatureRESET-RA | — | RESET-RArheumatoid arthritis+3 | — | 14m 48s | |
| 12/22/25 | E130: Telitacicept for SLE✨ | rheumatologyclinical trials+4 | — | telitaciceptFDA+3 | — | telitaciceptSLE+4 | — | 13m 06s | |
| 12/4/25 | E129: Long Term Routine Laboratory Monitoring in RA✨ | laboratory monitoringrheumatoid arthritis+3 | — | ACR Convergence 2025E129: Long Term Routine Laboratory Monitoring in RA+1 | — | rheumatoid arthritislaboratory monitoring+3 | — | 15m 17s | |
| 11/12/25 | E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)✨ | autoimmune diseasespulmonary fibrosis+3 | — | nerandomilastNEJM | autoimmune ILD | nerandomilastautoimmune ILD+3 | — | 19m 03s | |
| 9/22/25 | E127: TNFs and All That CHF✨ | safetyTNFs+3 | — | TNFsCHF+3 | — | TNFsCHF+4 | — | 21m 46s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 9/8/25 | E126: Risk Signals, JAKs, and SELECTIVE-ity✨ | rheumatologyJAK inhibitors+4 | — | ScienceDirectORAL-SURVEILLANCE+1 | — | rheumatoid arthritisJAKs+5 | — | 14m 34s | |
| 6/29/25 | E125: Adrenal Insufficiency after Stopping Prednisone✨ | adrenal insufficiencyprednisone+3 | — | prednisoloneJAMA Open | — | adrenal insufficiencyprednisone+3 | — | 17m 52s | |
| 6/12/25 | e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study | Interesting NEJM trial this week comparing methotrexate to prednisone for pulmonary sarcoidosis. Paper available here: https://www.nejm.org/doi/full/10.1056/NEJMoa2501443 | 14m 18s | ||||||
| 4/30/25 | E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA | Podcast this week about the recently published SELECT-GCA study, which evaluated the use of the janus kinase inhibitor upadacitinib (Rinvoq) for patients with new and relapsing GCA. Successful trial and an interesting topic. Paper itself here: https://www.nejm.org/doi/full/10.1056/NEJMoa2413449 | 18m 13s | ||||||
| 4/17/25 | E122: Guidelines for Maybe Diagnosing HLH | This week I cover another of my newsletters, though I mostly use it as a skeleton to riff on a common (and challenging) issue for rheumatology consultants; diagnosing HLH. Check out the guidelines themselves here and have a listen to the podcast! https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00273-4/fulltext | 11m 18s | ||||||
| 4/2/25 | E121: Obinutuzumab in SLE-LN | Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent obinutuzumab in lupus nephritis. Worth a read and listen, paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965 | 18m 14s | ||||||
| 3/6/25 | E120: Real Life Use of PEXIVAS-Low | What do you do when observational data and RCTs conflict? This week I'm covering the "real world PEXIVAS" study that was done by the French Vasculitis Study Group. Great read, interesting issues, have a listen and be sure to share with friends! | 24m 33s | ||||||
| 2/10/25 | E119: Teclistamab for Rheumatology Writ Large | One of my rare case-report podcasts, a topic that I typically avoid. The craze about CAR-T has also made me a little crazy, though, so I wanted to share what I think may be the ultimate destination for "more B cell depletion than rituximab" strategies. Article: https://www.nejm.org/doi/full/10.1056/NEJMc2407150 | 10m 52s | ||||||
| 1/31/25 | E118: The emerging risk of overdiagnosis in RA and PMR | Podcast this week about overdiagnosis! Currently one of my favorite topics and something that I think will be an emerging issue in our field. We recently published a Viewpoint in Lancet Rheumatology (https://pubmed.ncbi.nlm.nih.gov/39341221/) addressing this issue. I'm going to read from it and after that will be giving a few final (spicy) thoughts on the topic. Hope you find it worthwhile! s | 16m 02s | ||||||
| 12/3/24 | E117: Inebilizumab for IgG4-RD (MITIGATE) | New RCT in a new disease with a new drug! But is it as shiny as one would hope? Interesting discussion today about what a trial means, how it will affect practice, and how we could do better as a field. Happy holidays everyone! | 12m 55s | ||||||
| 11/11/24 | E116: A New Paradigm for PMR | Reading one of my recent newsletters this week, this one about PMR tapers. Be sure to subscribe at ebrheum.com if you want access to the visuals and upcoming editions! | 9m 29s | ||||||
| 10/28/24 | E115: Benralizumab for EGPA - the MANDARA Study | Quick rundown of an important rheumatology RCT this week, discussing the IL-5 inhibitor benralizumab for the treatment of relapsing/refractory EGPA. MANDARA Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2311155 | 9m 52s | ||||||
| 10/14/24 | E114: Target Trials and STAR-RA with Rishi Desai | Important methodology podcast this week, covering a lot of ground with expert epidemiologist Rishi Desai. Really enjoyed our conversation and glad to be publishing today! **House Keeping Note: we actually recorded this ~15 months ago but I somehow lost the audio... which somehow re-appeared! #technology STAR-RA: https://pubmed.ncbi.nlm.nih.gov/35027405/ | 31m 15s | ||||||
| 9/30/24 | E113: CAR-T is Coming to Rheumatology | Exciting podcast this week about the upcoming / impending use of CAR-T in rheumatology. Highly recommend rheumatologists learn about this now; it's going to be a big thing for many years to come. In a future episode I will lay out my case for skepticism, but for now I think a good run down of the first big published series will be enough! NEJM CAR-T Case Series: https://www.nejm.org/doi/full/10.1056/NEJMoa2308917 Nature Review Article: https://www.nature.com/articles/s41584-024-01139-z | 14m 04s | ||||||
| 9/12/24 | E112: Gabapentin is Trash | This week's podcast will be a quick read of one of my newsletters. The title basically speaks for itself! Find the newsletter and my other work at ebrheum.com | 6m 07s | ||||||
Showing 25 of 100
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
10 placements across 9 markets.
Chart Positions
10 placements across 9 markets.